HIGHLIGHTS
- who: Eu-IGFD Registry et al. from the Harvard Medical School, United States Queen Mary University of London have published the research work: Dynamics in Children With Severe Primary IGF-1 Deficiency: Results, in the Journal: (JOURNAL) of 13/05/2019
- what: The aim of the Eu-IGFD Registry is to collect long-term safety data on the use of mecasermin (rhIGF-1) for the treatment of children and adolescents with growth failure, including SPIGFD. The analysis presented in this manuscript covers data collected up to 13 of May 2019 and focuses on the effect . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.